459 related articles for article (PubMed ID: 1846761)
1. High molecular weight kininogen inhibits thrombin-induced platelet aggregation and cleavage of aggregin by inhibiting binding of thrombin to platelets.
Puri RN; Zhou F; Hu CJ; Colman RF; Colman RW
Blood; 1991 Feb; 77(3):500-7. PubMed ID: 1846761
[TBL] [Abstract][Full Text] [Related]
2. Modulation of thrombin-induced platelet aggregation by inhibition of calpain by a synthetic peptide derived from the thiol-protease inhibitory sequence of kininogens and S-(3-nitro-2-pyridinesulfenyl)-cysteine.
Puri RN; Matsueda R; Umeyama H; Bradford HN; Colman RW
Eur J Biochem; 1993 May; 214(1):233-41. PubMed ID: 8389701
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of ADP-induced platelet activation by 7-chloro-4-nitrobenz-2-oxa-1,3-diazole: covalent modification of aggregin, a putative ADP receptor.
Puri RN; Colman RW
J Cell Biochem; 1996 Apr; 61(1):97-108. PubMed ID: 8726359
[TBL] [Abstract][Full Text] [Related]
4. Thrombin-induced platelet aggregation involves an indirect proteolytic cleavage of aggregin by calpain.
Puri RN; Zhou FX; Bradford H; Hu CJ; Colman RF; Colman RW
Arch Biochem Biophys; 1989 Jun; 271(2):346-58. PubMed ID: 2543293
[TBL] [Abstract][Full Text] [Related]
5. Platelet activation by 2-(4-bromo-2,3-dioxobutylthio)adenosine 5'-diphosphate is mediated by its binding to a putative ADP receptor, aggregin.
Puri RN; Colman RF; Colman RW
Eur J Biochem; 1996 Mar; 236(3):862-70. PubMed ID: 8665907
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of ADP-induced platelet shape change and aggregation by o-phthalaldehyde: evidence for covalent modification of cysteine and lysine residues.
Puri RN; Colman RW
Arch Biochem Biophys; 1991 May; 286(2):419-27. PubMed ID: 1910292
[TBL] [Abstract][Full Text] [Related]
7. Cleavage of a 100 kDa membrane protein (aggregin) during thrombin-induced platelet aggregation is mediated by the high affinity thrombin receptors.
Puri RN; Zhou FX; Colman RF; Colman RW
Biochem Biophys Res Commun; 1989 Aug; 162(3):1017-24. PubMed ID: 2475104
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of ADP-induced platelet responses by covalent modification of aggregin, a putative ADP receptor, by 8-(4-bromo-2,3-dioxobutylthio)ADP.
Puri RN; Kumar A; Chen H; Colman RF; Colman RW
J Biol Chem; 1995 Oct; 270(41):24482-8. PubMed ID: 7592664
[TBL] [Abstract][Full Text] [Related]
9. Human kininogens regulate thrombin binding to platelets through the glycoprotein Ib-IX-V complex.
Bradford HN; Dela Cadena RA; Kunapuli SP; Dong JF; Löpez JA; Colman RW
Blood; 1997 Aug; 90(4):1508-15. PubMed ID: 9269768
[TBL] [Abstract][Full Text] [Related]
10. Role of cyclic AMP in adenosine inhibition of intracellular calcium rise in human platelets. Comparison of adenosine effects on thrombin- and epinephrine-induced platelet stimulation.
Feoktistov IA; Paul S; Hollister AS; Robertson D; Biaggioni I
Am J Hypertens; 1992 Jun; 5(6 Pt 2):147S-153S. PubMed ID: 1321639
[TBL] [Abstract][Full Text] [Related]
11. PPACK-thrombin inhibits thrombin-induced platelet aggregation and cytoplasmic acidification but does not inhibit platelet shape change.
Greco NJ; Tenner TE; Tandon NN; Jamieson GA
Blood; 1990 May; 75(10):1989-90. PubMed ID: 2337670
[TBL] [Abstract][Full Text] [Related]
12. Thrombin-induced platelet aggregation is inhibited by the heptapeptide Leu271-Ala277 of domain 3 in the heavy chain of high molecular weight kininogen.
Kunapuli SP; Bradford HN; Jameson BA; DeLa Cadena RA; Rick L; Wassell RP; Colman RW
J Biol Chem; 1996 May; 271(19):11228-35. PubMed ID: 8626672
[TBL] [Abstract][Full Text] [Related]
13. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways.
Krishnamurthi S; Westwick J; Kakkar VV
Biochem Pharmacol; 1984 Oct; 33(19):3025-35. PubMed ID: 6091666
[TBL] [Abstract][Full Text] [Related]
14. Low molecular weight kininogen binds to platelets to modulate thrombin-induced platelet activation.
Meloni FJ; Schmaier AH
J Biol Chem; 1991 Apr; 266(11):6786-94. PubMed ID: 2016293
[TBL] [Abstract][Full Text] [Related]
15. Human platelet activation is inhibited by the occupancy of glycoprotein IIb/IIIa receptor.
Padoin E; Alexandre A; Cavallini L; Polverino de Laureto P; Rao GH; Doni MG
Arch Biochem Biophys; 1996 Sep; 333(2):407-13. PubMed ID: 8809080
[TBL] [Abstract][Full Text] [Related]
16. Antiplatelet effect of marchantinquinone, isolated from Reboulia hemisphaerica, in rabbit washed platelets.
Liao CH; Ko FN; Wu CL; Teng CM
J Pharm Pharmacol; 2000 Mar; 52(3):353-9. PubMed ID: 10757426
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of rabbit platelet aggregation by 1,4-naphthoquinones.
Ko FN; Sheu SJ; Liu YM; Huang TF; Teng CM
Thromb Res; 1990 Feb; 57(3):453-63. PubMed ID: 2156351
[TBL] [Abstract][Full Text] [Related]
18. Autoantibodies to kininogen-phosphatidylethanolamine complexes augment thrombin-induced platelet aggregation.
Sugi T; McIntyre JA
Thromb Res; 1996 Oct; 84(2):97-109. PubMed ID: 8897699
[TBL] [Abstract][Full Text] [Related]
19. High molecular weight kininogen binds to platelets by its heavy and light chains and when bound has altered susceptibility to kallikrein cleavage.
Meloni FJ; Gustafson EJ; Schmaier AH
Blood; 1992 Mar; 79(5):1233-44. PubMed ID: 1536948
[TBL] [Abstract][Full Text] [Related]
20. Halysin, an antiplatelet Arg-Gly-Asp-containing snake venom peptide, as fibrinogen receptor antagonist.
Huang TF; Liu CZ; Ouyang CH; Teng CM
Biochem Pharmacol; 1991 Aug; 42(6):1209-19. PubMed ID: 1888330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
